PMID- 25095521
OWN - NLM
STAT- MEDLINE
DCOM- 20140909
LR  - 20231213
IS  - 0890-9016 (Print)
IS  - 0890-9016 (Linking)
DP  - 2013
TI  - Anti-HLA-E monoclonal antibodies reacting with HLA-la and lb alleles like IVIg as 
      potential IVIg-immunomimetics: an evolving therapeutic concept.
PG  - 293-305
AB  - Healthy individuals have natural antibodies (Abs) reacting to allo-human 
      leukocyte antigen (HLA)-la. This could be due to the presence of anti-HLA-E 
      immunoglobulin G (IgG), which was revealed to recognize the peptides shared 
      between HLA-E and HLA-la after peptide inhibition assay. Sera or plasma of 
      multiple donors are pooled to prepare intravenous immune globulin (IVIg). The 
      HLA-la-reactivity of IVIg is abolished when the anti-HLA-E Abs are depleted from 
      the IVIg, suggesting that IVIg contains anti-HLA-E Abs with HLA-la reactivity. 
      Anti-HLA-E monoclonal antibodies (mAbs; e.g., TFL-006 and TFL-007) generated at 
      Terasaki Foundation Laboratory (TFL) differ from commercial HLA-E mAbs in 
      mimicking HLA-la &-lb reactivities of IVIg, which is known to suppress the 
      allo-HLA antibody (Ab) production and the activated CD4+ T cells. Whether 
      HLA-E-mAbs also have the ability to suppress the production of these Abs and 
      activation of T cells like IVIg is evaluated. Indeed, the TFL-mAbs significantly 
      suppressed the allo-HLA-ll Ab production by B cells obtained from a woman 
      alloimmunized postpartum >20 years ago. Similarly, the TFL-mAbs suppressed HLA-I 
      Ab produced by a B-cell hybridoma. In both instances, the suppression was far 
      superior to that by IVIg. Activated T cells were suppressed by both IVIg and the 
      TFL-mAbs dosimetrically. Furthermore, the required concentrations of TFL-mAbs are 
      150-fold lower than the concentrations of IVIg required for the suppression.
FAU - Ravindranath, Mepur H
AU  - Ravindranath MH
FAU - Zhu, Dong
AU  - Zhu D
FAU - Pham, Tho
AU  - Pham T
FAU - Jucaud, Vadim
AU  - Jucaud V
FAU - Hopfield, Judy
AU  - Hopfield J
FAU - Kawakita, Satoru
AU  - Kawakita S
FAU - Terasaki, Paul I
AU  - Terasaki PI
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - Clin Transpl
JT  - Clinical transplants
JID - 8812419
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (HLA Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Antibodies, Monoclonal/*immunology/*therapeutic use
MH  - HLA Antigens/*immunology
MH  - Histocompatibility Antigens Class I/*immunology
MH  - Humans
MH  - Immunoglobulins, Intravenous/*immunology/therapeutic use
MH  - Transplantation Immunology/*immunology
MH  - HLA-E Antigens
EDAT- 2013/01/01 00:00
MHDA- 2014/09/10 06:00
CRDT- 2014/08/07 06:00
PHST- 2014/08/07 06:00 [entrez]
PHST- 2013/01/01 00:00 [pubmed]
PHST- 2014/09/10 06:00 [medline]
PST - ppublish
SO  - Clin Transpl. 2013:293-305.